Scribd
Upload
65 views8 pages

Pharmatrac Oct22

The Indian pharma industry showed a growth of 7.2% in value and a decline of 1.0% in units for October 2022, with strong performance in Cardiac, Derma, Respiratory, and Gynaec therapies, while Anti-infectives experienced value degrowth. A webinar on industry performance for September 2022 is scheduled for November 7, 2022, with registration required. The document also includes insights on inter-department coordination from Mr. Alok Malik of Glenmark Pharmaceuticals.

Uploaded by

TejasNaik
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
65 views8 pages

Pharmatrac Oct22

The Indian pharma industry showed a growth of 7.2% in value and a decline of 1.0% in units for October 2022, with strong performance in Cardiac, Derma, Respiratory, and Gynaec therapies, while Anti-infectives experienced value degrowth. A webinar on industry performance for September 2022 is scheduled for November 7, 2022, with registration required. The document also includes insights on inter-department coordination from Mr. Alok Malik of Glenmark Pharmaceuticals.

Uploaded by

TejasNaik
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

INDUSTRY MAILER

INDIAN PHARMA INDUSTRY PERFORMANCE

Oct 2022 Dataset

1
The Content of this Industry Mailer is property of AWACS. Any replication/publication without authorization would amount to legal action
Therapy Performance

Growth for the Month of


OCT 22 is 7.2% in terms of
Value and -1.0% in terms
of Units.

Among the top therapies,


Cardiac, Derma,
Respiratory and Gynaec
have shown a robust value
growth.

Anti-infectives is the only


therapy among the top
therapies that has shown
value degrowth.

Source: PHARMATRAC AWACS MAT OCT 2022


VAL IN CR ; UNITS IN 000 The Content of this Industry Mailer is property of AWACS. Any replication/publication without authorization would amount to legal action
Quarterly Growth Drivers

Source: PHARMATRAC AWACS MAT OCT 2022


VAL IN CR ; UNITS IN 000 The Content of this Industry Mailer is property of AWACS. Any replication/publication without authorization would amount to legal action
Top 20 Corporates

Source: PHARMATRAC AWACS MAT OCT 2022


VAL IN CR ; UNITS IN 000 The Content of this Industry Mailer is property of AWACS. Any replication/publication without authorization would amount to legal action
Top 20 Brands
Rank G/L: MAT OCT 22 Rank Over MAT SEP 22 Rank / MTH OCT 22 Rank Over MTH SEP 22 Rank
Sales Val = Actual Val + Bonus Val

Source: PHARMATRAC AWACS MAT OCT 2022


VAL IN CR ; UNITS IN 000 The Content of this Industry Mailer is property of AWACS. Any replication/publication without authorization would amount to legal action
Opinions That Matter

Topic : Essentials of Inter Department Co-ordination to


Leverage The First Mover Advantage

Speaker : Mr Alok Malik, Executive Vice President and Business Head

Company : Glenmark Pharmaceuticals Ltd

Source: PHARMATRAC AWACS MAT OCT 2022


VAL IN CR ; UNITS IN 000 The Content of this Industry Mailer is property of AWACS. Any replication/publication without authorization would amount to legal action
Webinar on Industry Performance for the month
of Sep 2022
Registration details
Date: 7th Nov 2022
Time: 10:30 am
Registration link: [Link]

You need to register on the above link from your official email id. You will receive a
confirmation link in your mailbox through which you can join the webinar.

Source: PHARMATRAC AWACS MAT OCT 2022


VAL IN CR ; UNITS IN 000 The Content of this Industry Mailer is property of AWACS. Any replication/publication without authorization would amount to legal action
For any further detail you can connect with us on

Pharmatracsupport@[Link]
[Link]

Source: PHARMATRAC AWACS MAT OCT 2022


VAL IN CR ; UNITS IN 000 The Content of this Industry Mailer is property of AWACS. Any replication/publication without authorization would amount to legal action

You might also like